BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corpor ...

Core Insights - Monte Rosa Therapeutics announced positive interim data from the Phase 1 clinical study of MRT-8102, a NEK7-directed molecular glue degrader aimed at treating inflammatory conditions linked to the NLRP3 inflammasome, IL-1, and IL-6 [2][3] Study Results - MRT-8102 demonstrated an 85% reduction in C-reactive protein (CRP) levels after four weeks of treatment, with 94% of participants achieving CRP values below 2 mg/L, indicating a lower cardiovascular disease (CVD) risk [1][3][8] - The study included single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, showing deep and sustained NEK7 degradation across doses from 5 mg to 400 mg [1][3] - A favorable safety profile was observed, with mild to moderate adverse events and no increased infection risk reported [1][7] Future Development Plans - The ongoing GFORCE-1 study of MRT-8102 in subjects with elevated CVD risk is being expanded to include multiple dose levels, with results anticipated in the second half of 2026 [1][5] - A Phase 2 study (GFORCE-2) for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) is planned to be initiated in 2026 [1][5] - Additional indications for MRT-8102 are being evaluated, including metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis [3][5] Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases, leveraging its QuEEN™ discovery engine [9]

– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidofludimus Calcium Reduced 24-Week Confirmed Disability Worsening and Increased 24-Week Confirmed Disability Improvement Across Progressive Multiple Sclerosis and Its Subtypes, Reinforcing the Drug's Direct Neuroprotective Mechanism of Action – – Long-Term Open-Label Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company's clinical trial plans ...

Core Insights - Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines [3] - The company will host a live conference call and webcast on January 7, 2026, to present interim clinical results from the Phase 1 study of the NEK7-directed MGD MRT-8102 [1] - The presentation will include interim data from the ongoing Part 3 CRP proof-of-concept cohort targeting subjects with elevated cardiovascular disease risk [1] Company Overview - Monte Rosa Therapeutics specializes in highly selective molecular glue degrader (MGD) medicines aimed at treating serious diseases [3] - The company's QuEEN™ discovery engine utilizes AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with high selectivity [3] - Monte Rosa has developed a leading pipeline of first-in-class and only-in-class MGDs, with three programs currently in clinical trials [3] - The company collaborates with major pharmaceutical firms in immunology, oncology, and neurology [3]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Company Overview - Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that treat intractable diseases through RNA interference (RNAi) therapeutics [1] - The company competes with other biotech firms in the RNAi space, including Alnylam Pharmaceuticals and Ionis Pharmaceuticals [1] Insider Trading Activity - On January 5, 2026, Hamilton James C, the Chief Medical Officer, sold 4,625 shares at $61.24 each, retaining 207,497 shares post-sale [2] - Mauro Ferrari, a Director, sold 7,530 shares at an average price of $70, totaling $527,100, and reduced his ownership by 9.83% [3] - Ferrari previously sold 8,750 shares at $56.39 each, totaling $493,412.50 [3] Stock Performance - Arrowhead's stock opened at $66.39, reflecting a 1.3% decrease, and is currently priced at $63.88, down 5.77% or $3.91 [4] - The stock has fluctuated between $60.62 and $68 during the trading day, with a yearly high of $72.36 and a low of $9.57 [4] - The company's market cap is approximately $8.83 billion [4] Trading Volume and Momentum - The trading volume for ARWR today is 2,692,400 shares [5] - The stock's 50-day moving average is $53.54, indicating recent upward momentum despite recent insider sales [5][6] - Arrowhead remains a significant player in the biopharmaceutical industry, focusing on RNAi therapeutics [6]

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than Ja ...

Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A inve... ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...